The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch

Highlights The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products Results support The Precision Peptide Company Inc.'s continued progression of its lead product toward commercial launch Independent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch¹ Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical benchmark for credible high purity grade peptide products² Testing performed by independent US analytical laboratory Miraxis Labs (San Diego, California), using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD), and certified by two PhD scientists Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today reports initial third-party test results for its needle free BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The Results Independent analytical laboratory Miraxis Labs, based in San Diego, California, has tested the patch and confirmed: 95.5% chromatographic purity 2.02 mg of BPC-157 per patch (quantified potency) Both results were measured using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD).